You are browsing the global website, which contains information intended for residents outside of the United States of America (U.S.). This website is not country-specific and therefore may contain information that is not applicable to your country.
Rare Cells, with Single Cell Precision
We offer a menu of FDA-cleared and laboratory-developed tests (LDTs) used to detect and analyze circulating tumor cells in human blood with CELLSEARCH®. This minimally invasive liquid biopsy approach allows these tests to enable optimized patient care and comfort throughout the patient’s therapeutic journey.
Learn more about our Oncology portfolio
Learn more about our commitment in cell-based noninvasive prenatal testing (CB-NIPT)
Find out more about billing options
Learn more about setting up your account and ordering a test
If you already have an existing portal account, you can login here
Discover how our clinical lab service can support biopharma partners and clinical trials
Discover how our custom research lab service can support research projects
Single Cell Analysis
FFPE Analysis
View our complete list of Laboratory Developed Tests
Read the latest news from the Menarini Group
2016 - 12 - 20
Only FDA-Cleared CTC test to join Company’s Portfolio of Diagnostics
Bologna, Italy and San Diego, CA, Dec 20, 2016 - Menarini-Silicon Biosystems today announced they have signed an agreement to purchase all the assets and relevant business related to the CELLSEARCH® Circulating Tumor Cell (CTC) system from Janssen Diagnostics, LLC. CELLSEARCH® is used to help manage patients with metastatic breast, prostate, and colorectal cancers. It is the only FDA-cleared CTC test, and has also been approved by China’s FDA for use in monitoring breast cancer patients. Financial details were not disclosed.
CELLSEARCH® system will join Menarini-Silicon Biosystems’ family of advanced diagnostics, which includes the Company’s flagship DEPArray™ System. DEPArray™ is a rare-cell detection and isolation technology that is used globally in a number of therapeutic areas, including oncology. With both DEPArray™ and CELLSEARCH® in its portfolio, Menarini-Silicon Biosystems will be able to provide CTC detection on an FDA-cleared platform, and give oncologists and researchers access to unparalleled molecular characterization capabilities. Together, the two technologies provide a unique opportunity to advance next-generation, personalized medicine strategies.
“We are excited to welcome CELLSEARCH® to the Menarini-Silicon Biosystems portfolio,” commented Lucia Aleotti, Chairman of Menarini Group and Giuseppe Giorgini, CEO, Menarini-Silicon Biosystems. “The combined capabilities of CELLSEARCH® together with our DEPArray™ System will enhance our potential to enable meaningful advances in the field of personalized medicine.”
Under terms of the agreement, when the closing will occur, Menarini-Silicon Biosystems will seek to retain many of the Janssen Diagnostics employees in roles dedicated to CTCs, and assume operation of Janssen Diagnostics’ CLIA-certified laboratory in Huntingdon Valley, Pennsylvania. The two companies will work closely to transition the business across the many global markets where CELLSEARCH® is available.
About CELLSEARCH ® Technology
Clinical data to date from 28 independent prospective studies involving more than 4,700 patients have validated the clinical performance and value of CELLSEARCH® CTC testing to predict progression-free survival and overall survival both before and after therapy initiation. CELLSEARCH® data have been published in more than 100 peer-reviewed publications.
About the DEPArray™ System
DEPArray™ technology is recognized as the gold standard to isolate single CTCs from enriched blood, with data published in 19 peer-reviewed publications and mentioned in more than 30 review articles. The full synergy between CELLSEARCH® enrichment and DEPArray™ sorting have been shown to deliver 100% pure cells suitable for very precise and reproducible downstream next-generation sequencing analysis. In addition, DEPArray™ technology has other applications that includes recovery and molecular characterization of pure cell populations from disaggregated formalin-fixed paraffin-embedded (FFPE) specimens, fresh tissues and fine needle aspiration samples.
About Menarini-Silicon Biosystems
Menarini-Silicon Biosystems Inc. is a Menarini Group company, with European headquarters in Bologna and American headquarters in San Diego, California. Menarini-Silicon Biosystems operates in the healthcare sector and in personalized medicine, through the development of technologies and products that help to understand the biological complexity of many pathologies thanks to the study of single cells. For more information www.siliconbiosystems.com
*The DEPArray™ system is for research-use only.
Read More
Login